Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tris-CAR-T cell therapy / Tasly
NCT05577091: Tris-CAR-T Cell Therapy for Recurrent Glioblastoma	Recruiting	1	10	RoW	Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes., Autologous Tris-CAR-T cell.	Beijing Tiantan Hospital, Beijing Neurosurgical Institute, Tasly Pharmaceutical Group Co., Ltd	Recurrent Glioblastoma	11/24	11/32